Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet’s Uveitis Not Responding to Conventional Therapy

ABSTRACT Purpose: To investigate the long-term efficacy and safety of interferon alpha-2a (IFNα-2a) in Chinese patients with Behçet’s uveitis (BU) refractory to conventional therapy. Methods: In a prospective observational cohort study, 127 patients were treated with an initial dosage of 3 million units per day in the first three months, followed by gradual tapering of the dose. Results: After 3 months of treatment, IFNα-2a was shown to be effective in 115 cases (91%). At the end of the 1-year follow-up, the frequency of ocular relapses decreased to 1.59 ± 1.68 per year (ranging 0–6) (p < 0.001), as compared to 5.09 ± 2.51 per year (ranging 3–15). Moreover, the frequency of oral ulcer relapses also decreased to 2.49 ± 1.84 per year (ranging 0–6) (p < 0.001), as compared to 8.20 ± 3.72 per year (ranging 2–10). Visual improvement or stability was observed in 32 patients (59%) in these 54 patients. During a mean follow-up of 11 months (range 3–33), the mean final VA (logMAR) had progressed from 1.0 logMAR to 0.8 logMAR in all treated patients. Conclusions: Long-term low dose of IFNα-2a is useful in treating Chinese BU patients who do not respond adequately to conventional therapy.

[1]  G. Hatemi,et al.  One year in review 2016: Behçet's syndrome. , 2016, Clinical and experimental rheumatology.

[2]  T. Arayssi,et al.  Update on the therapy of Behçet disease , 2014, Therapeutic advances in chronic disease.

[3]  İ. Tuğal-Tutkun,et al.  Therapy of Ocular Behçet Disease , 2014, Ocular immunology and inflammation.

[4]  Gianni Virgili,et al.  Reading aids for adults with low vision. , 2013, The Cochrane database of systematic reviews.

[5]  H. Direskeneli,et al.  Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. , 2011, Archives of ophthalmology.

[6]  R. Vonthein,et al.  Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. , 2010, Arthritis and rheumatism.

[7]  A. Bayer,et al.  Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. , 2010, Ophthalmology.

[8]  H. Lemij,et al.  Foveal cone photoreceptor involvement in primary open-angle glaucoma , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  A. Kijlstra,et al.  Immune Response Genes in Uveitis , 2009, Ocular immunology and inflammation.

[10]  J. Kempen,et al.  Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. , 2008, American journal of ophthalmology.

[11]  J. Piette,et al.  Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. , 2008, American journal of ophthalmology.

[12]  Q. Meng,et al.  Clinical features of chinese patients with Behçet's disease. , 2008, Ophthalmology.

[13]  J. Piette,et al.  Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients , 2006, British Journal of Ophthalmology.

[14]  İ. Tuğal-Tutkun,et al.  Results of interferon-alfa therapy in patients with Behçet uveitis , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[15]  S. Androudi.  Current concepts in the etiology and treatment of Behçet disease. , 2006, Survey of ophthalmology.

[16]  B. Wechsler,et al.  Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. , 2005, American journal of ophthalmology.

[17]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[18]  A. Bayer,et al.  ORIGINAL ARTICLE, Interferon Alpha-2A Treatment for Serpiginous Choroiditis , 2005 .

[19]  R. Vonthein,et al.  Influence of human recombinant interferon-α2a (rhIFN-α2a) on altered lymphocyte subpopulations and monocytes in Behçet's disease , 2004 .

[20]  İ. Tuğal-Tutkun,et al.  Uveitis in Behçet disease: an analysis of 880 patients. , 2004, American journal of ophthalmology.

[21]  M. Zierhut,et al.  The use of interferon α in behçet disease: review of the literature , 2004 .

[22]  H. Messner,et al.  Rescue of Interferon Induced Bone Marrow Aplasia in a Patient with Chronic Myeloid Leukemia by Allogeneic Bone Marrow Transplant , 2004, Leukemia & lymphoma.

[23]  R. Vaughan,et al.  Behçet’s disease: from Hippocrates to the third millennium , 2003, The British journal of ophthalmology.

[24]  J. Renard,et al.  Panuvéite bilatérale récidivante familiale : efficacité de l’interféron alpha , 2003 .

[25]  R. Vonthein,et al.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis , 2003, The British journal of ophthalmology.

[26]  J. Schulman,et al.  Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. , 2003, Ophthalmology.

[27]  J. Piette,et al.  Visual loss during interferon-alpha therapy in hepatitis C virus infection. , 2002, Journal of Hepatology.

[28]  Y. Ozyazgan,et al.  Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. , 2002, The Israel Medical Association journal : IMAJ.

[29]  J. Piette,et al.  Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease , 2000, Ocular immunology and inflammation.

[30]  C. Lohmann,et al.  Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma , 1999, The Lancet.

[31]  P. Tugwell,et al.  Pharmacotherapy for Behcet's syndrome. , 1998, The Cochrane database of systematic reviews.

[32]  L. Emmi,et al.  Immunopathological aspects of Behçet's disease. , 1995, Clinical and experimental rheumatology.

[33]  M. Colombo,et al.  Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. , 1995, European journal of endocrinology.

[34]  G. Krueger,et al.  Bone marrow hypoplasia and fibrosis following interferon treatment. , 1994, In vivo.

[35]  S. Seeber,et al.  Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. , 1992, Clinical immunology and immunopathology.

[36]  G. Fattovich,et al.  Autoantibodies during α‐interferon therapy for chronic hepatitis B , 1991 .

[37]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Nussenblatt,et al.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.

[39]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[40]  A. Silman,et al.  [Criteria of diagnosis of Behcet's disease]. , 1975, La Tunisie medicale.

[41]  Mamta,et al.  Ocular Immunology and Inflammation , 2016 .

[42]  A. Kijlstra,et al.  Molecular Genetic Advances in Uveitis. , 2015, Progress in molecular biology and translational science.

[43]  M. Zierhut,et al.  The use of interferon alpha in Behçet disease: review of the literature. , 2004, Seminars in arthritis and rheumatism.

[44]  J. Renard,et al.  [Familial recurrent bilateral panuveitis: efficiency of alpha interferon]. , 2003, La Revue de medecine interne.

[45]  L. Kanz,et al.  Influence of interferon-alpha on lymphocyte subpopulations in Behçet's disease. , 2003, Advances in experimental medicine and biology.

[46]  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. , 1990, Lancet.